Core Insights - The pharmaceutical distribution industry is a crucial component of the national healthcare system and health industry, significantly impacting public health and safety [1][7] - The industry is experiencing growth due to the implementation of the "two-invoice system" reform and increasing public awareness of healthcare [1][7] Industry Overview - The pharmaceutical distribution market in China is projected to reach a sales volume of 29,470 billion yuan in 2024, with wholesale sales accounting for 22,970 billion yuan (77.94%) and retail sales for 6,500 billion yuan (22.06%) [1][7] - The regional distribution of sales shows that East China accounts for 36.3%, Central South 27.0%, North China 15.2%, Southwest 13.4%, Northeast 4.3%, and Northwest 3.8%, with the top three regions contributing to 78.5% of total sales [9][10] Sales Structure - The sales composition indicates that Western medicine accounts for 70.8% of total sales, followed by traditional Chinese medicine at 14.6%, medical devices at 7.7%, and other categories [9][10] Current State of the Industry - As of the end of 2024, there are 705,400 licensed pharmaceutical businesses in China, including 15,100 wholesale companies and 66,070 retail chain enterprises [3][5] - The total number of retail pharmacies has increased to 683,700, with a notable rise in single retail pharmacies [3][5] Financial Performance - In 2024, the main business income of reported pharmaceutical distribution enterprises reached 22,431 billion yuan, reflecting a 0.8% increase from 2023, while the profit totaled 468 billion yuan with an average gross margin of 7.2% [5][6] Industry Chain - The pharmaceutical distribution industry serves as a critical link in the pharmaceutical supply chain, connecting manufacturers with end-users, including hospitals and pharmacies [11][12] Competitive Landscape - Major players in the pharmaceutical distribution sector include East China Pharmaceutical, Shanghai Pharmaceutical, China National Pharmaceutical Group, and others, with significant revenue contributions from these companies [14][15] Future Development Directions - The industry aims to enhance operational efficiency and inventory management to ensure a stable supply of pharmaceuticals while minimizing financial risks [18][19]

【最新百强医药批发和零售企业发布：国药集团和大参林位居榜首】2025年12月8日，商务部官网发布 了《2024年药品流通行业运行统计分析报告》。2024年前10大医药批发企业分别是：国药集团、上海医 药、华润医药、九州通、重庆医药—中国医药联合体、广州医药、南京医药、华东医药、英特集团、海 王生物。 2024年前10大医药零售企业分别是：大参林、益丰药房、国大药房、老百姓、一心堂、同仁堂、健之 佳、漱玉平民、好药师、河南张仲景大药房。 2024年，全国药品流通市场销售规模略有增长。统计显示，全国七大类医药商品销售总额为29470亿 元，扣除不可比因素同比增长0.6%。其中，药品零售市场销售额为6500亿元，扣除不可比因素同比增 长1.3%；药品批发市场销售额为22970亿元，扣除不可比因素同比增长0.5%。 截至2024年年底，全国共有《药品经营许可证》持证企业70.54万家。其中批发企业1.51万家，同比增加 0.03万家；零售连锁企业6607家，同比减少118家；下辖门店39万家，同比增加0.44万家；零售单体药店 29.37万家，同比增加1.23万家。零售药店总数68.37万家，同比增加1.67万家。 ...

从资金流向上来看，当日医药商业板块主力资金净流出9.95亿元，游资资金净流入2.16亿元，散户资金净 流入7.78亿元。医药商业板块个股资金流向见下表： 证券之星消息，12月8日医药商业板块较上一交易日上涨0.26%，瑞康医药领涨。当日上证指数报收于 3924.08，上涨0.54%。深证成指报收于13329.99，上涨1.39%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002589 | 瑞康医药 | 4.69 | 10.09% | 551.02万 | | 25.16 Z | | 603122 | 合當中国 | 29.18 | 9.99% | 20.78万 | | 6.05亿 | | 600538 | 国发股份 | 6.63 | 4.08% | 27.35万 | | 1.80亿 | | 002788 | 醫症医药 | 11.32 | 4.04% | 1 70.14万 | | 7.89亿 | | 600829 | 人民同泰 | 13.72 | 3 ...

证券代码：600998 证券简称：九州通公告编号：临2025-085 九州通医药集团股份有限公司 关于股东提前解除股份质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●公司股东上海弘康和北京点金分别办理完成31,000,000股和37,000,000股的股份提前解除质押手续，本 次提前解除质押股份占其所持股份比例分别为2.85%和13.38%，占公司总股本的比例分别为0.61%和 0.73%；同时，上海弘康和北京点金分别办理完成52,750,000股和37,000,000股的股份质押手续，本次质 押股份占其所持股份比例分别为4.85%和13.38%，占公司总股本的比例分别为1.05%和0.73%。 ●截至2025年12月4日，公司股东上海弘康和北京点金分别持有公司股份1,088,326,782股和276,531,424 股，占公司总股本的比例分别为21.58%和5.48%。本次股份提前解除质押及质押办理完成后，上海弘康 和北京点金分别累计质押公司股份654,324,549股和37,000,00 ...

九州通医药集团股份有限公司 关于股东提前解除股份质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●公司股东上海弘康和北京点金分别办理完成31,000,000股和37,000,000股的股份提 前解除质押手续，本次提前解除质押股份占其所持股份比例分别为2.85%和13.38%，占 公司总股本的比例分别为0.61%和0.73%；同时，上海弘康和北京点金分别办理完成 52,750,000股和37,000,000股的股份质押手续，本次质押股份占其所持股份比例分别为 4.85%和13.38%，占公司总股本的比例分别为1.05%和0.73%。 ●截至2025 年12月4日，公司股东上海弘康和北京点金分别持有公司股份 1,088,326,782股和276,531,424股，占公司总股本的比例分别为21.58%和5.48%。本次股 份提前解除质押及质押办理完成后，上海弘康和北京点金分别累计质押公司股份 654,324,549股和37,000,000股，占其所持股份的比例分别为60.12%和13.38%，占公司 ...

Core Points - 九州通吉钦供应链管理（上海）有限公司 has been established with a registered capital of 5 million RMB, fully owned by 九州通方协医疗技术服务（上海）有限公司 [1] - The company operates in the supply chain management sector and offers a variety of services including technical services, medical equipment leasing, and health consulting [1] Company Overview - Company Name: 九州通吉钦供应链管理（上海）有限公司 [1] - Legal Representative: 李娲 [1] - Registered Capital: 5 million RMB [1] - Business Scope: Supply chain management services, technical services, medical equipment leasing, health consulting, and sales of various medical and electronic products [1] - Business Type: Other limited liability company [1] - Registration Authority: 金山区市场监管局 [1] Industry Context - The company is categorized under the rental and business services industry, specifically within comprehensive management services [1] - The operational address is located in 金山区, 上海 [1] - The business license allows for a range of activities, subject to regulatory approvals for certain projects [1]

Group 1 - The core point of the news is that Jiuzhoutong's major shareholders have completed the early release and pledge of shares, with significant portions of their holdings being pledged [1] - As of November 23, 2025, the controlling shareholder Chuchang Investment and its concerted party Zhongshan Guangyin hold approximately 460 million shares and 335 million shares, accounting for 9.11% and 6.65% of the total share capital respectively [1] - After the completion of the share pledge and release, Chuchang Investment and Zhongshan Guangyin have pledged approximately 234 million shares and 320 million shares, representing 50.89% and 95.33% of their respective holdings, and 4.64% and 6.34% of the total share capital [1] Group 2 - For the first half of 2025, Jiuzhoutong's revenue composition shows that pharmaceutical wholesale and related businesses account for 95.94%, pharmaceutical manufacturing for 1.96%, pharmaceutical retail for 1.84%, healthcare and technology services for 0.17%, and other businesses for 0.08% [1] - As of the report date, Jiuzhoutong's market capitalization is 24.8 billion yuan [1]

九州通公告称，2025年11月21日，控股股东楚昌投资提前解除质押1600万股，占其所持股份3.48%，占 总股本0.32%；股东中山广银质押7000万股，占其所持股份20.87%，占总股本1.39%。截至11月23日， 控股股东及其一致行动人合计持股22.91亿股，占总股本45.43%，累计质押12.97亿股，占其所持股份 56.63%，占总股本25.73%。部分质押股份将在未来半年和一年内到期，控股股东及其一致行动人具备 还款能力，对公司无影响。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600998 证券简称：九州通 公告编号：临 2025-084 九州通医药集团股份有限公司 关于控股股东及其一致行动人提前解除股份质押及质押的公告 重要内容提示： ●公司控股股东楚昌投资办理完成16,000,000股的股份提前解除质押手续，本次提前 解除质押股份占其所持股份的比例为3.48%，占公司总股本的比例为0.32%。同时，公司 股东中山广银办理完成70,000,000股的股份质押手续，本次质押股份占其所持股份的比 例为20.87%，占公司总股本的比例为1.39%。 ●截至2025年11月23日，公司控股股东楚昌投资及其一致行动人中山广银分别持有 公司股份459,506,100股和335,357,275股，占公司总股本的比例分别为9.11%和6.65%。本 次股份提前解除质押及质押办理完成后，楚昌投资和中山广银分别累计质押公司股份 233,830,980股和319,696,820股，占其所持股份的比例分别为50.89%和95.33%，占公司总 股本的比例分别为4. ...

Core Viewpoint - Two major pharmaceutical groups, Jiuzhoutong and Guangzhou Pharmaceutical Group, are acquiring distressed companies to strengthen their respective business segments in the medical aesthetics and IVD (in vitro diagnostics) industries [1][2]. Group 1: Jiuzhoutong's Acquisition of Aoyuan Meigu - Jiuzhoutong's wholly-owned subsidiary is investing in Aoyuan Meigu, which has entered a restructuring process due to ongoing financial losses and debt crises [1][2]. - Aoyuan Meigu, which ventured into the medical aesthetics sector in 2020, has been struggling with significant operational losses and was unable to repay debts, leading to a restructuring application [2][3]. - If the restructuring is successful, Jiuzhoutong plans to leverage its strong pharmaceutical supply chain and operational management experience to enhance collaboration with Aoyuan Meigu in the beauty and health sector [4]. Group 2: Guangzhou Pharmaceutical Group's Acquisition of Da'an Gene - Guangzhou Pharmaceutical Group is acquiring 100% equity of Guangyong Technology, which will indirectly give it control over 2.33 billion shares of Da'an Gene, amounting to a total investment of 908 million yuan [1]. - Da'an Gene, initially a university-run enterprise, has faced significant declines in performance, with a 90.20% drop in revenue and a 98.07% drop in net profit in 2023 [3]. - The acquisition aims to resolve internal issues at Da'an Gene and expand Guangzhou Pharmaceutical Group's business footprint in the IVD sector, creating a comprehensive "diagnosis + treatment + health management" industry chain [5]. Group 3: Industry Environment - Both the medical aesthetics and IVD sectors have moved past the most stringent regulatory challenges, allowing for greater pricing flexibility for compliant institutions [6]. - The ongoing price reductions in the IVD sector have led to a concentration of market share among leading companies, presenting a favorable opportunity for cash-rich players to acquire distressed assets [6].